The central dogma of molecular biology is a fundamental concept
in the study of biology, found in all major biology curricula
(NGSS, non-NGSS state-level life science, AP, IB, and
undergraduate Vision and Change) and biology textbooks.
Educators can therefore use this interactive in a variety of
courses, ranging from first-year high school biology to
undergraduate molecular biology electives. The connection to
genetic techniques and their applications extends its use to
biotechnology-focused courses.
Exploration of this interactive ties to several science
practices including the use of models and representations,
engagement in scientific questioning, construction of
evidence-based explanations, and relating knowledge across
scales and concepts. The interactive will also emphasize key
crosscutting concepts that help students better understand core
ideas in science including the importance of structure and
function; scale; and cause and effect.
Educators should keep in mind that the flow of information from
DNA to RNA to protein is a dynamic process that involves many
more steps and molecules than are shown in this interactive. In
addition, there are exceptions to this orderly flow. For
example, scientists have discovered that noncoding RNA and
retroviruses are capable of reverse transcription, in which
genetic information flows from RNA to DNA. Educators might also
remind students that, except for cancer, diseases featured in
this interactive are rare monogenic diseases, caused by
mutations in single genes. It will be more challenging to apply
these technologies to more common diseases caused by a
combination of genes and environmental factors. In most cases,
more than one treatment strategy or technology may be applied to
any particular disease.
References
CRISPR
You Lu (Sichuan University), "PD-1 Knockout Engineered T Cells
for Metastatic Non-Small Cell Lung Cancer," accessed July 31,
2017,
https://clinicaltrials.gov/ct2/show/NCT02793856?term=crispr&rank=6.
Leber Congenital Amaurosis
James W.B. Bainbridge et al., "Effect of Gene Therapy
on Visual Function in Leber's Congenital Amaurosis,"
New England Journal of Medicine 358, no. 21 (May 22,
2008): 2231–39, doi:10.1056/NEJMoa0802268.
Oscar Francisco Chacon-Camacho and Juan Carlos Zenteno,
"Review and Update on the Molecular Basis of Leber Congenital
Amaurosis,"
World Journal of Clinical Cases 3, no. 2 (February
16, 2015): 112, doi:10.12998/wjcc.v3.i2.112.
Sickle Cell
CDC, "Data and Statistics | Sickle Cell Disease | NCBDDD |
CDC," 2016, https://www.cdc.gov/ncbddd/sicklecell/data.html.
Christian Brendel et al., "Lineage-Specific BCL11A
Knockdown Circumvents Toxicities and Reverses Sickle
Phenotype," Journal of Clinical Investigation 126,
no. 10 (September 6, 2016): 3868–78, doi:10.1172/JCI87885.
Huntington's Disease
Michael D. Rawlins et al., "The Prevalence of Huntington's
Disease,"
Neuroepidemiology 46, no. 2 (2016): 144–53,
doi:10.1159/000443738.
Holly B. Kordasiewicz et al., "Sustained Therapeutic
Reversal of Huntington's Disease by Transient Repression of
Huntingtin Synthesis," Neuron 74, no. 6 (June 2012):
1031–44, doi:10.1016/j.neuron.2012.05.009.
Ionis Pharmaceuticals, "Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in
Patients With Early Manifest Huntington's Disease - Full Text
View - ClinicalTrials.gov," 2015,
https://clinicaltrials.gov/ct2/show/NCT02519036.
Duchenne Muscular Dystrophy
Alan E.H. Emery, "Population Frequencies of Inherited
Neuromuscular Diseases—A World Survey,"
Neuromuscular Disorders 1, no. 1 (1991): 19–29,
doi:10.1016/0960-8966(91)90039-U.
Maria Kinali et al., "Local Restoration of Dystrophin
Expression with the Morpholino Oligomer AVI-4658 in Duchenne
Muscular Dystrophy: A Single-Blind, Placebo-Controlled,
Dose-Escalation, Proof-of-Concept Study,"
Lancet Neurol. 8 (2009), doi:10.1016/S1474.
Cystic Fibrosis
Michael R. Kosorok, Wen-Hsiang Wei, and Philip M. Farrell,
"The Incidence of Cystic Fibrosis,"
Statistics in Medicine 15, no. 5 (March 15, 1996):
449–62,
doi:10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X.
Kelly Kuk and Jennifer L. Taylor-Cousar, "Lumacaftor and
Ivacaftor in the Management of Patients with Cystic Fibrosis:
Current Evidence and Future Prospects,"
Therapeutic Advances in Respiratory Disease
9, no. 6 (December 2015): 313–26,
doi:10.1177/1753465815601934.